The Blood Collection Market is expected to grow at a CAGR of 6.2% during the forecast period, 2022-2027.
The outbreak of COVID-19 worldwide is expected to positively impact the market because blood testing involves the testing of various blood samples, which helps diagnose infectious diseases such as COVID-19. Testing remains a crucial step in controlling the COVID-19 pandemic. As the number of COVID-19 cases is increasing worldwide, governments across the globe are exploring the possibilities of allowing private laboratories to ramp up blood testing. Moreover, the blood reserves have been depleting due to the virus outbreak. Many individuals with weak immune systems who have been infected by COVID-19 and are hospitalized need a blood/plasma transfusion. Many governments are also taking initiatives to help increase blood donation. For instance, in June 2020, the Maharashtra state government in India used social media initiatives to increase the number of blood donations. The move was taken following the shortage of blood in the region. Such programs have positively impacted the global blood collection market growth in many regions during the pandemic.
Specific factors driving the market growth include the rising demand for early diagnosis of chronic conditions, increasing incidence of trauma and accidents, and a surge in the number of surgical procedures carried out worldwide.
Blood collection has also witnessed a great demand due to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders. Cancers such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS) can affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system. It has been observed that apheresis technology has been used to reduce the number of white cells until other medications can control them. According to the Leukemia and Lymphoma Society (LLS) Factsheet 2021, approximately every three minutes, one person in the United States is diagnosed with blood cancer. Moreover, as per the same source, 186,400 people in the United States will be diagnosed with leukemia and lymphoma in 2021. In addition, 825,651 people lived with lymphoma in the United States, 152,671 people resided with Hodgkin lymphoma, and 672,980 people lived with non-Hodgkin lymphoma.
Moreover, the growing number of accidents also boosts the market growth. According to the World Health Organization, 2020, 1.35 million people die yearly from road accidents, and 20-50 million suffer from non-fatal injuries. The increasing number of accidents drives the demand for blood products, boosting the market growth.
The steady increase in the number of patients suffering from these diseases and ailments and the growing number of accidents may boost the blood collection market during the forecast period. However, blood contamination, other complications, and injuries caused during the blood collection are the major restraining factor for the market studied.
The immediate detection of COVID-19 cases requires the wide availability of diagnostics to control the virus's rapid spread. A public health emergency was determined, justifying the authorization of emergency use of in vitro diagnostics (IVDs) to diagnose COVID-19, which ultimately drives blood testing worldwide. Hence, the needles and syringes segment is expected to see healthy growth over the forecast period. Using hypodermic needles and syringes is the most common means of blood sampling. Therefore, blood collection needles and syringes are expected to dominate the market owing to their extensive use all across the globe.
Apart from the pandemic, many other infectious diseases are prevalent, increasing the demand for blood specimen collection for diagnosis, thereby boosting the demand for needles and syringes for blood collection. For instance, in the study titled "The Order of Draw during Blood Collection: A Systematic Literature Review," published in the MDPI Journal in February 2021, a syringe with a needle is a common open blood collection system. Syringes are an essential part of any phlebotomist's blood-collection device toolkit. Thus, the demand for syringes and needles in fore blood collection boosted the segment growth over the forecast period.
Various advancements in the field of medical devices are also fueling market growth. For example, According to the study titled "Variation of the Penetration Effort in an Artificial Tissue by Hypodermic Needles," published in the Hindwi Journal in September 2020, siliconized needles are currently being used in multiple instances to minimize trauma and minimize the risk of vein cross perforation with a short bevel. Because a vast number of injuries occur within seconds after an invasive device is removed from the vein, the majority of the marketed needles provide immediate protection at the puncture site. Hence, this segment is expected to retain its dominance in the global market over the forecast period.
North America holds the largest share of the market studied, which is attributed to the increasing demand for blood collection products. An increase in the number of road accidents and the rising prevalence of chronic diseases are the major factors driving the growth of the market studied. With the COVID-19 impact being the highest in the United States, the region foresees good growth in the market during the forecast period.
According to the American National Red Cross, 2021 updated estimates, approximately 36,000 units of red blood cells are needed every day, and nearly 21 million blood components are transfused each year in the United States. Additionally, according to the Globocan 2020 report, Canada had 8,506 cases of Non-Hodgkin lymphoma and 313 deaths caused due to it in 2020. The increase in cases of Non-Hodgkin lymphoma is expected to boost the demand for the blood collection market.
However, various strategies acquired by the key market players in the country anticipated market growth. For instance, in December 2021, Ethos Laboratories, a College of American Pathologists-accredited and certified leader in diagnostic testing services, launched Tru-Immune, a finger prick, self-collection kit for its COVID-19 neutralizing antibody test.
Additionally, in December 2021, Tasso, a maker of simplified blood collection devices. After raising only USD 17 million to begin operations in mid-2020, the company has raised USD 100 million to expand its production and commercial reach for advanced at-home blood collection devices. The growing number of chronic diseases and lifestyle-related disorders requires blood collection for their diagnosis, which boosts the region's market growth.
The blood collection market is highly competitive and consists of several major players. Companies like Becton, Dickinson and Company, Cardinal Health, F.L. Medical SRL, Greiner Bio-One International GmbH, Haemonetics Corporation, Henry Schein Inc., McKesson Corporation, Medline Industries Inc., PreQ Systems, and Qiagen, among others, hold substantial shares in the market.
This product will be delivered within 2 business days.
The outbreak of COVID-19 worldwide is expected to positively impact the market because blood testing involves the testing of various blood samples, which helps diagnose infectious diseases such as COVID-19. Testing remains a crucial step in controlling the COVID-19 pandemic. As the number of COVID-19 cases is increasing worldwide, governments across the globe are exploring the possibilities of allowing private laboratories to ramp up blood testing. Moreover, the blood reserves have been depleting due to the virus outbreak. Many individuals with weak immune systems who have been infected by COVID-19 and are hospitalized need a blood/plasma transfusion. Many governments are also taking initiatives to help increase blood donation. For instance, in June 2020, the Maharashtra state government in India used social media initiatives to increase the number of blood donations. The move was taken following the shortage of blood in the region. Such programs have positively impacted the global blood collection market growth in many regions during the pandemic.
Specific factors driving the market growth include the rising demand for early diagnosis of chronic conditions, increasing incidence of trauma and accidents, and a surge in the number of surgical procedures carried out worldwide.
Blood collection has also witnessed a great demand due to an increased number of patients suffering from various ailments related to blood, kidney, metabolic diseases, and neurological disorders. Cancers such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS) can affect the bone marrow, blood cells, lymph nodes, and other parts of the lymphatic system. It has been observed that apheresis technology has been used to reduce the number of white cells until other medications can control them. According to the Leukemia and Lymphoma Society (LLS) Factsheet 2021, approximately every three minutes, one person in the United States is diagnosed with blood cancer. Moreover, as per the same source, 186,400 people in the United States will be diagnosed with leukemia and lymphoma in 2021. In addition, 825,651 people lived with lymphoma in the United States, 152,671 people resided with Hodgkin lymphoma, and 672,980 people lived with non-Hodgkin lymphoma.
Moreover, the growing number of accidents also boosts the market growth. According to the World Health Organization, 2020, 1.35 million people die yearly from road accidents, and 20-50 million suffer from non-fatal injuries. The increasing number of accidents drives the demand for blood products, boosting the market growth.
The steady increase in the number of patients suffering from these diseases and ailments and the growing number of accidents may boost the blood collection market during the forecast period. However, blood contamination, other complications, and injuries caused during the blood collection are the major restraining factor for the market studied.
Key Market Trends
Needles and Syringes are Expected to Hold a Significant Market Share
The immediate detection of COVID-19 cases requires the wide availability of diagnostics to control the virus's rapid spread. A public health emergency was determined, justifying the authorization of emergency use of in vitro diagnostics (IVDs) to diagnose COVID-19, which ultimately drives blood testing worldwide. Hence, the needles and syringes segment is expected to see healthy growth over the forecast period. Using hypodermic needles and syringes is the most common means of blood sampling. Therefore, blood collection needles and syringes are expected to dominate the market owing to their extensive use all across the globe.
Apart from the pandemic, many other infectious diseases are prevalent, increasing the demand for blood specimen collection for diagnosis, thereby boosting the demand for needles and syringes for blood collection. For instance, in the study titled "The Order of Draw during Blood Collection: A Systematic Literature Review," published in the MDPI Journal in February 2021, a syringe with a needle is a common open blood collection system. Syringes are an essential part of any phlebotomist's blood-collection device toolkit. Thus, the demand for syringes and needles in fore blood collection boosted the segment growth over the forecast period.
Various advancements in the field of medical devices are also fueling market growth. For example, According to the study titled "Variation of the Penetration Effort in an Artificial Tissue by Hypodermic Needles," published in the Hindwi Journal in September 2020, siliconized needles are currently being used in multiple instances to minimize trauma and minimize the risk of vein cross perforation with a short bevel. Because a vast number of injuries occur within seconds after an invasive device is removed from the vein, the majority of the marketed needles provide immediate protection at the puncture site. Hence, this segment is expected to retain its dominance in the global market over the forecast period.
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America holds the largest share of the market studied, which is attributed to the increasing demand for blood collection products. An increase in the number of road accidents and the rising prevalence of chronic diseases are the major factors driving the growth of the market studied. With the COVID-19 impact being the highest in the United States, the region foresees good growth in the market during the forecast period.
According to the American National Red Cross, 2021 updated estimates, approximately 36,000 units of red blood cells are needed every day, and nearly 21 million blood components are transfused each year in the United States. Additionally, according to the Globocan 2020 report, Canada had 8,506 cases of Non-Hodgkin lymphoma and 313 deaths caused due to it in 2020. The increase in cases of Non-Hodgkin lymphoma is expected to boost the demand for the blood collection market.
However, various strategies acquired by the key market players in the country anticipated market growth. For instance, in December 2021, Ethos Laboratories, a College of American Pathologists-accredited and certified leader in diagnostic testing services, launched Tru-Immune, a finger prick, self-collection kit for its COVID-19 neutralizing antibody test.
Additionally, in December 2021, Tasso, a maker of simplified blood collection devices. After raising only USD 17 million to begin operations in mid-2020, the company has raised USD 100 million to expand its production and commercial reach for advanced at-home blood collection devices. The growing number of chronic diseases and lifestyle-related disorders requires blood collection for their diagnosis, which boosts the region's market growth.
Competitive Landscape
The blood collection market is highly competitive and consists of several major players. Companies like Becton, Dickinson and Company, Cardinal Health, F.L. Medical SRL, Greiner Bio-One International GmbH, Haemonetics Corporation, Henry Schein Inc., McKesson Corporation, Medline Industries Inc., PreQ Systems, and Qiagen, among others, hold substantial shares in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton, Dickinson and Company
- Cardinal Health
- Terumo Corporation
- FRESENIUS KABI
- Haemonetics Corporation
- Henry Schein Inc.
- McKesson Corporation
- Medline Industries Inc.
- PreQ Systems
- Qiagen
- Grifols
- Smiths Medical
- Quest Diagnostics
- Nipro Medical Corporation
Methodology
LOADING...
